To determine whether ISG15 contributes to the progression of ccRCC by regulating the JAK2/STAT3 signaling pathways, we used the JAK2/STAT3 pathway inhibitor FLLL32 and the activator recombinant human IL6 in rescue experiments. Here, JAK2 is linked to nonpapillary renal cell carcinoma.